New GLP-1 Weight Loss Pill Foundayo Approved with Flexible Usage Guidelines

Want the full story?
Read the complete article at KVIA
AI Summary
The FDA has approved Foundayo, a new GLP-1 weight loss pill developed by Eli Lilly, offering a more flexible option for those seeking obesity treatment. Unlike the Wegovy pill, which must be taken on an empty stomach, Foundayo can be consumed at any time of day without dietary restrictions. The drug is expected to be available for home shipping starting April 6, with a monthly cost ranging from $149 to $399, depending on the dosage. Medicare coverage will begin on July 1 for eligible patients. This new medication aims to increase accessibility for the millions of Americans struggling with obesity, as current injectable options are underutilized.
Key Details: • Foundayo will be available for home shipping starting April 6. • Monthly out-of-pocket costs range from $149 to $399 based on dosage. • Medicare coverage begins on July 1, with a copay of no more than $50. • Patients should consult their doctors regarding birth control effectiveness while on Foundayo.